BioCentury | Jan 5, 2015
Strategy

Guest Commentary: The Tipping Point

...NYSE:ABBV) Imbruvica ibrutinib (A) Pharmacyclics Inc. (NASDAQ:PCYC)/Johnson & Johnson (NYSE:JNJ) KTE-C19 Kite Pharma Inc. (NASDAQ:KITE) Otlertuzumab...
BioCentury | Jan 6, 2014
Clinical News

Otlertuzumab: Interim Phase Ib/II data

...II portion of the open-label, U.S. Phase Ib/II Study 16201 showed that 20 mg/kg IV otlertuzumab...
...and commercialize otlertuzumab as a result of a portfolio prioritization process. Abbott gained rights to otlertuzumab...
...Roche markets it as MabThera elsewhere. Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Product: Otlertuzumab ( TRU-016...
BioCentury | Jan 6, 2014
Clinical News

Otlertuzumab: Interim Phase Ib data

...20 mg/kg IV otlertuzumab for 8 weeks followed by once-monthly doses of 20 mg/kg IV otlertuzumab...
...and commercialize otlertuzumab as a result of a portfolio prioritization process. Abbott gained rights to otlertuzumab...
...Roche markets it as MabThera elsewhere. Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Product: Otlertuzumab ( TRU-016...
BioCentury | May 13, 2013
Clinical News

TRU-016: Completed Phase Ib/II enrollment

...Study 16201 of IV TRU-016 given in 28-day cycles. The Phase II portion is comparing TRU-016...
...Study 16201 of IV TRU-016 given in 28-day cycles. The Phase II portion is comparing TRU-016...
...Treanda alone. TRU-016 has Orphan Drug designation in the U.S. and EU for CLL. Product: TRU-016...
BioCentury | Apr 15, 2013
Clinical News

TRU-016: Phase Ib amended

...Emergent amended an open-label, U.S. Phase Ib trial evaluating IV TRU-016 given weekly for 8 weeks...
...2 additional cohorts of 16 patients each. Patients in the cohorts will receive 6 m/kg TRU-016...
...The trial initially planned to enroll about 24 previously untreated patients to receive 10 mg/kg TRU-016...
BioCentury | Jan 7, 2013
Clinical News

TRU-016 regulatory update

...Emergent said the European Commission granted Orphan Drug designation for TRU-016 to treat chronic lymphocytic leukemia...
...as a result of a portfolio prioritization process, according to Emergent. Abbott gained rights to TRU-016...
...2010; Aug. 16, 2010 & Jan. 2, 2012). Emergent BioSolutions Inc. (NYSE:EBS), Rockville, Md. Product: TRU-016...
BioCentury | Nov 12, 2012
Clinical News

TRU-016: Phase Ib/II data

...open-label Phase Ib portion of a Phase Ib/II trial showed that 15 and 20 mg/kg TRU-016...
...in Atlanta in December. Patients in the Phase Ib portion received 15 and 20 mg/kg TRU-016...
...selected in the first portion plus Treanda vs. Treanda alone in up to 100 patients. TRU-016...
BioCentury | Nov 5, 2012
Clinical News

TRU-016: Phase Ib started

...Emergent began an open-label, U.S. Phase Ib trial to evaluate IV TRU-016 given weekly for 8...
...patients. Patients will receive 10 mg/kg TRU-016 for the first dose and 20 mg/kg thereafter. TRU-016...
...as a result of a portfolio prioritization process, according to Emergent. Abbott gained rights to TRU-016...
BioCentury | Jan 2, 2012
Finance

Highlights of weekly biotech stock moves

...after saying Abbott Laboratories (NYSE:ABT) will terminate a 2009 deal to co-develop and commercialize Emergent's TRU-016...
...payment from Abbott, which was triggered by the start of a Phase II trial of TRU-016...
BioCentury | Jan 2, 2012
Company News

Emergent BioSolutions, Abbott deal

...Emergent said Abbott will terminate a 2009 deal to co-develop and commercialize Emergent's cancer product TRU-016...
...Emergent a $6 million payment triggered by the start of a Phase II trial of TRU-016...
...non-Hodgkin's lymphoma (NHL). Data from the trials are expected by 1H13. Abbott gained rights to TRU-016...
Items per page:
1 - 10 of 42